# Hassan Mahmudul

> Hassan Mahmudul is a seed investor at Future Planet Capital backing Health Care and Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Future Planet Capital](https://shizune.co/investors/profile/future-planet-capital)
- Location: London, United Kingdom
- Total investments: 6
- Last investment: Mar 2026
- Lead investor: 17%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/hassan-mahmudul-04ab33123/

Hassan Mahmudul is a venture capital investor at Future Planet Capital, he is also a graduate of the Durham University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 33% |
| Biotechnology | 2 | 33% |
| Medical | 1 | 17% |
| Life Science | 1 | 17% |
| Test and Measurement | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cytotrait | Cytotrait focuses on the development of novel traits for food and agriculture. | $4M | Seed | Mar 09, 2026 |  |
| iFast Diagnostics | iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $6.5M | Seed | Nov 04, 2024 |  |
| Adamo Foods | Adamo Food is a UK-based food tech company developing plant-based whole-cut meats using proprietary fermentation technology combined with mycelium. | $2.5M | Seed | Aug 12, 2024 |  |
| Vitarka Therapeutics | Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom. | $1.6M | Seed | Apr 06, 2023 |  |
| iFast Diagnostics | iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $2.4M | Seed | Feb 16, 2023 |  |
| Zentraxa | Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent previously existingbio-design limits imposed by conventional peptide synthesis, with one universal process. |  | Seed | May 27, 2022 |  |

6 of 6 investments shown.

## Co-investors
- [Meridian Health Ventures](https://shizune.co/investors/profile/khp-ventures) — VC Fund, 3 deals together
- [QantX](https://shizune.co/investors/profile/qantx) — VC Fund, 3 deals together
- [Empirical Ventures](https://shizune.co/investors/profile/empirical-ventures) — VC Fund, 2 deals together
- [Kadmos Capital](https://shizune.co/investors/profile/kadmos-capital-43dd) — VC Fund, 2 deals together
- [Beeches Group](https://shizune.co/investors/profile/beeches-group) — VC Fund, 1 deal together
- [Bristol Private Equity Club](https://shizune.co/investors/profile/bristol-private-equity-club) — VC Fund, 1 deal together

## About Future Planet Capital

VC Fund · London, United Kingdom

Future Planet is an impact-led venture capital firm that invests in technology and life science companies from leading research centres

5 contacts available at Future Planet Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Guy Pengelley | Investment Director | https://shizune.co/investors/profile/guy-pengelley-dbac |
| Douglas Hansen-Luke | founder | https://shizune.co/investors/profile/douglas-hansen-luke |
| Hassan Mahmudul | VC Investor | https://shizune.co/investors/profile/hassan-mahmudul |
| Lyle Pentith | Portfolio Manager | https://shizune.co/investors/profile/ed-phillips-2ce1 |
| Oliver Sexton | Head of Life Science | https://shizune.co/investors/profile/oliver-sexton |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Hassan Mahmudul invest in?

Hassan Mahmudul invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hassan Mahmudul last invest?

The most recent investment recorded for Hassan Mahmudul closed in Mar 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co